Linsley P S, Ochs V, Laska S, Horn D, Ring D B, Frankel A E, Brown J P
Cancer Res. 1986 Oct;46(10):5444-50.
A novel screening assay was used to test 13 previously described antibreast cancer antibodies for those which recognize antigens elevated in serum of breast cancer patients. Binding of three of these antibodies to breast or lung carcinoma cells was inhibited to a significantly greater extent by tumor patient serum than by normal serum, suggesting that the antigens might be useful serum markers. Two of these antibodies, W1 and W9, were shown to recognize nonoverlapping epitopes on a high molecular weight molecule(s) purified from serum from breast cancer patients. A sensitive double determinant immunoassay was developed to measure W1 antigen levels in sera from a total of 389 cancer patients and controls. Forty seven % (37 of 79) of individuals having breast cancer showed elevated serum levels of the W1 antigen, whereas only 4% (1 of 25) of normal controls and 2% (1 of 47) of patients hospitalized for nonmalignant disorders showed elevated levels. These differences were statistically significant (P less than 0.001). The percentage of breast cancer patients showing elevated serum levels was greater for individuals with metastatic disease. Statistically significant numbers of lung, ovarian, and prostate, but not colon, cancer patients also had elevated serum levels of the W1 antigen. These data suggest that measurement of the W1 antigen in serum might provide clinically useful information on the course of metastatic breast and other cancers.
一种新型筛选试验被用于检测13种先前描述的抗乳腺癌抗体，以寻找那些能识别乳腺癌患者血清中升高抗原的抗体。与正常血清相比，肿瘤患者血清对其中三种抗体与乳腺癌或肺癌细胞结合的抑制作用显著更强，这表明这些抗原可能是有用的血清标志物。其中两种抗体W1和W9被证明可识别从乳腺癌患者血清中纯化出的高分子量分子上不重叠的表位。开发了一种灵敏的双决定簇免疫测定法来检测总共389名癌症患者和对照血清中的W1抗原水平。47%（79例中的37例）乳腺癌患者血清中W1抗原水平升高，而正常对照中只有4%（25例中的1例），因非恶性疾病住院的患者中只有2%（47例中的1例）出现升高水平。这些差异具有统计学意义（P小于0.001）。有转移疾病的乳腺癌患者血清水平升高的比例更高。在肺癌、卵巢癌和前列腺癌患者中，血清W1抗原水平升高的人数具有统计学意义，但结肠癌患者中没有。这些数据表明，检测血清中的W1抗原可能为转移性乳腺癌和其他癌症的病程提供临床上有用的信息。
